Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
1.
Adv Radiat Oncol ; 8(3): 101034, 2023.
Article in English | MEDLINE | ID: mdl-37273924

ABSTRACT

Purpose: Changes in patient anatomy and tumor geometry pose a challenge to ensuring consistent target coverage and organ-at-risk sparing; online adaptive radiation therapy (ART) accounts for these interfractional changes by facilitating replanning before each treatment. This project explored the opportunity cost of computed tomography (CT)-based online ART by evaluating time and human resource requirements. Time-driven activity-based costing (TDABC) was employed to determine the cost of this time to assess if the dosimetric benefit is worthwhile. Methods and Materials: CT-based online ART was recently employed at our institution and has been used to treat pelvic disease sites (prostate, prostate bed, prostate with nodal coverage, bladder, rectum); data points from all adaptively treated patients (415 fractions) were used. Time taken for each adaptive fraction before treatment, which at our facility is best represented by the duration between 2 cone beam CT scans, was used as a broadly applicable and transferable metric, representing the additional time required for ART on top of standard image guided radiation therapy. Dosimetric effect was also considered by taking the difference of planning target volume V100% for the scheduled and adapted plans. Using recently validated TDABC at this facility, the per fraction cost of ART was determined, reflecting the added cost of ART on top of image guided radiation therapy. Results: A median time of 15.97 (interquartile range, 13.23-18.83) additional minutes was required for each adaptive fraction. TDABC demonstrated an average minimum cost per adapted fraction of $103.58. Dosimetric differences between V100% of the scheduled versus adapted plan showed a mean dosimetric difference of 15.8%. Conclusions: Although online ART decreases the uncertainty of anatomic shifts, each adaptive fraction requires more staff time, delaying completion of other tasks and increasing resource utilization. Although toxicity benefits require further studies, the implementation of progressively complex radiation therapy technologies, like ART, requires consideration of the time and human resource requirements and subsequent opportunity cost.

2.
Int J Radiat Oncol Biol Phys ; 116(2): 334-347, 2023 06 01.
Article in English | MEDLINE | ID: mdl-36669542

ABSTRACT

Disproportionate sex, racial, and ethnic diversity remains in the radiation oncology physician workforce despite widespread awareness and longitudinal efforts to improve representation. In this collaborative review, we define the rationale and components of holistic review and how it can be best used to provide a comprehensive evaluation of applicants to residency programs in radiation oncology. We initially discuss the current state of diversity in the field of radiation oncology and highlight the components of the residency selection process that may serve to perpetuate existing biases. Subsequently, the Accreditation Council for Graduate Medical Education and Association of American Medical Colleges holistic review framework is reviewed in detail to demonstrate the balanced assessment of potential applicants. The implementation of holistic review in medical school and residency selection to date is examined to underscore the potential value of holistic review in the radiation oncology residency selection process. Finally, recommendations for the practical implementation of holistic review in radiation oncology trainee selection are outlined.


Subject(s)
Internship and Residency , Radiation Oncology , Humans , Radiation Oncology/education , Education, Medical, Graduate , Accreditation , Cultural Diversity
3.
J Med Imaging Radiat Sci ; 53(4): 659-663, 2022 12.
Article in English | MEDLINE | ID: mdl-36216733

ABSTRACT

OBJECTIVE: Currently, there are no consensus guidelines about handling incidental radiological findings on radiotherapy planning CT simulation scans. Retrospective studies analyzing incidental findings on CT simulations show a small, but not insignificant, rate of both oncologic and non-oncologic findings. These findings may have medico-legal, financial, and clinical implications. Given a lack of guidelines, we obtained a formal survey of multiple academic institutions to evaluate how CT simulations are handled in regard to incidental findings. METHODS: A formal survey was developed consisting of 12 questions related to institutional practices regarding CT simulation scans. From 7/18/21 to 8/27/21 and 5/6/22 to 5/24/22, the survey was administered electronically by REDCap to key personnel at Academic Radiation Oncology Programs identified through the American Society for Radiation Oncology (ASTRO) with inclusion criteria including an active ACGME approved Radiation Oncology residency program. RESULTS: In total, 88 academic radiation oncology programs were surveyed with total of 45 responses (51%). 1 out of 45 departments who responded has formal guidelines regarding workup of incidental findings. There is variability about sending CT simulation scans for official radiology review if an incidental finding is identified. CONCLUSIONS: Based on a measurable rate of incidental findings on radiotherapy planning CT simulations and their possible implications, our survey illustrates a likely need for consensus recommendations for handling such findings to improve patient care and safety.


Subject(s)
Radiation Oncology , Radiology , Humans , United States , Incidental Findings , Retrospective Studies , Tomography, X-Ray Computed
4.
Sarcoma ; 2022: 2091677, 2022.
Article in English | MEDLINE | ID: mdl-36046749

ABSTRACT

Background: Radiation after resection of an atypical lipomatous tumor (ALT) is controversial. This study evaluates local control and complications after the first resection of ALTs of the extremity with or without adjuvant radiation. Methods: A dual institution, retrospective review of patients treated from 1995 to 2020 with first-time resection of an ALT in the extremity was performed. In total, 102 patients underwent adjuvant radiation (XRT group) and 68 patients were treated with surgery alone (no-XRT group). The median follow-up time was 4.6 years (interquartile range (IQR) 2.0-7.3 years). The median radiation dose was 60 Gy (IQR 55-66 Gy). Univariable and multivariable analyses evaluated the association of patient, tumor, and treatment variables with recurrence and complications. Kaplan-Meier analysis evaluated local recurrence-free survival (LRFS) and time to complication. Results: The overall incidence of local recurrence was 1% (1/102) in the XRT group and 24% (16/68) in the no-XRT group (p < 0.001). The median time-to-recurrence was 8.2 years (IQR 6.5-10.5 years). In the XRT and the no-XRT groups, 5-yr LRFS was 98% and 92% (p=0.21) and 10-yr LRFS was 98% and 41% (p < 0.001), respectively. The absence of radiation (HR = 23.63, 95% CI (3.09-180.48); p < 0.001) and R2 surgical resection margins (HR = 11.04, 95% CI (2.07-59.03); p < 0.001) incurred a 23-fold and 11-fold increased risk of local recurrence, respectively, while tumor size, depth, location, and neurovascular involvement were not found to be independent predictors of recurrence. The complication rate was 37% (38/102) in the XRT group and 10% (7/68) in the no-XRT group (p < 0.001). Eight patients (8/102, 8%) required surgical management for complication in the XRT group compared with two patients (2/68, 3%) in the no-XRT group (p=0.10). Higher radiation dose had a modest correlation with increased severity of complication (ρ=0.24; p=0.02). Conclusions: Adjuvant radiation after first-time resection of an ALT of the extremity was associated with a significantly reduced risk of local recurrence but a three-fold increase in complication rate. These data support a 10-year follow-up for these patients and inform a notable clinical trade-off if considering adjuvant radiation for this tumor with recurrent potential.

5.
Adv Radiat Oncol ; 6(6): 100755, 2021.
Article in English | MEDLINE | ID: mdl-34934855

ABSTRACT

PURPOSE: SpaceOAR is a device approved for conventional radiation in prostate cancer. We sought to observe prospectively how SpaceOAR Hydrogel effected quality of life and dosimetry to organs at risk at our institution. METHODS AND MATERIALS: We prospectively enrolled patients with low risk or favorable-intermediate risk localized prostate cancer. Baseline Expanded Prostate Cancer Index Composite (EPIC-26) scores along with baseline American Urology Association Symptom Index (AUA-SI) scores were collected. SpaceOAR was placed for all patients who then received stereotactic body radiation therapy, low dose rate brachytherapy, conventionally fractionated radiation therapy, or moderately hypofractionated radiation therapy. We evaluated postimplant dosimetry to critical structures, and prospectively collected follow-up EPIC-26 and AUA-SI scores. We performed a repeated measures analysis of variance to compare patient-specific responses and correlated survey data with dosimetric metrics by generating linear regression models. RESULTS: We enrolled 59 patients in this study with a median follow-up of 366 days (interquartile range, 507). At final follow-up, the "?>prostate-specific antigen had a significant decline compared with baseline (P < .0001). There were no grade 3 toxicities on treatment. There were no significant changes in the AUA-SI score (P = .69) at final follow-up compared with baseline, nor was there any change in EPIC-26 domain scores (P = .19) during the course of the study period. There were no significant associations between AUA scores and EPIC-26 scores and the dose to the rectum, bladder, or urethra with the exception being dose to the 2 mL rectum correlated with decline in EPIC-26 rectal score (ß, -0.002; P = .006). Patient-reported declines in bowel domains were less than previously reported data. CONCLUSIONS: Use of SpaceOAR results in favorable dosimetry to the organs at risk and portends excellent short-term quality of life as measured by the association with the patient reported outcome measures. Longer-term follow-up is ongoing and necessary to assess the long-term effect and association of the hydrogel.

6.
Pract Radiat Oncol ; 11(1): 84-88, 2021.
Article in English | MEDLINE | ID: mdl-32416269

ABSTRACT

PURPOSE: A recent clinical trial has demonstrated that noninvasive radioablation (NIRA) has the potential to reduce recurrent ventricular tachycardia (VT) that is refractory to drugs and standard catheter ablation. Electroanatomic mapping (EAM) that would be useful for planning is obtained during catheter ablation, but incompatibility between EAM and DICOM formats required for radiation planning has impeded the use of existing catheter-based mapping to guide NIRA and is an important hurdle for its wider adoption. In this paper we define a process to facilitate the fusion of catheter-based EAM with DICOM imaging for radiation planning. METHOD AND MATERIALS: The raw data export of the CARTO3 EAM system (version 6.0.45.171, ".mesh" file) was processed with a MATLAB script to generate 3-dimensional (3D) visual took kit files containing X, Y, Z coordinates obtained during mapping and corresponding impedance, voltage, and other point-based information. The image could then be visualized with standard image processing software (3D Slicer) and the target outlined on the image surface. This structure was in turn converted to a DICOM image and fused with patient thoracic imaging using anatomic landmarks. Robustness of the workflow was assessed through implementation with a second magnetic resonance imaging based VT ablation planning system, ADAS-VT. RESULTS: This process facilitated the fusion of EAM and DICOM imaging to inform selection of NIRA targets. The workflow was found to be robust and compatible with a second VT ablation planning system. CONCLUSIONS: The conversion of catheter-based EAM to a DICOM compatible format permits the fusion of images for radiation planning and provides an avenue for the wider application of NIRA. Further improvements in the compatibility of these imaging formats would be expected to improve quality and reproducibility of image fusion.


Subject(s)
Imaging, Three-Dimensional , Tachycardia, Ventricular , Catheters , Humans , Reproducibility of Results , Tachycardia, Ventricular/diagnostic imaging , Workflow
7.
Int J Surg Oncol ; 2020: 8374790, 2020.
Article in English | MEDLINE | ID: mdl-33489372

ABSTRACT

INTRODUCTION: Inadvertent excision of a soft tissue sarcoma during hernia surgery is a preventable clinical scenario that leads to unnecessary patient morbidity. Prior series are few, which only include male patients with little focus on prevention. The purpose of this study is to report the presenting features and outcomes of both male and female patients who underwent inadvertent inguinal sarcoma excision during hernia surgery. METHODS: A retrospective analysis of a single sarcoma referral center identified 33 patients who were referred for definitive treatment. Patients were divided into three clinically relevant groups based on intraoperative diagnosis, sex, and location of the mass relative to the inguinal ligament. T-tests and Fisher's exact tests were performed to compare continuous and categorical variables, respectively. Kaplan-Meier modeling was performed to assess sarcoma-specific survival. RESULTS: Females were younger (47 years vs. 61 years, p=0.003) and had smaller sarcomas (6.7 cm vs. 11 cm, p=0.012) compared to males. Only two sarcomas (2/33, 6%) were <4 cm in size. The majority of sarcomas in females were above the inguinal ligament (12/14, 86%). Twenty-nine (88%) underwent definitive R0 excision. The mean number of surgeries per patient was three (range 1-13), with nineteen (58%) patients requiring flap reconstruction and six (18%) requiring vascular bypass. Five patients locally recurred (15%) at a mean of 38 months after definitive excision (range 5-128 months). Overall sarcoma-specific disease-free survival was 64%, with no difference between males (80 ± 11%) and females (59 ± 17%) (p=0.885). Mean follow-up was 75 months (range 5-212). CONCLUSION: This is the second largest study regarding inadvertent inguinal sarcoma excision and the first to include females. When a suspected hernia is >4 cm, irreducible, firm, and is growing, especially in females, consider obtaining preoperative advanced three-dimensional imaging (CT or MRI) that can differentiate a neoplasm from a hernia.


Subject(s)
Hernia, Inguinal/diagnosis , Neoplasm Recurrence, Local , Sarcoma/diagnosis , Sarcoma/surgery , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Diagnostic Errors , Disease-Free Survival , Female , Hernia, Inguinal/surgery , Humans , Incidental Findings , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Recurrence, Local/pathology , Reoperation , Retrospective Studies , Sarcoma/pathology , Soft Tissue Neoplasms/pathology , Survival Rate , Tumor Burden , Young Adult
8.
Comput Biol Med ; 102: 376-380, 2018 11 01.
Article in English | MEDLINE | ID: mdl-30126615

ABSTRACT

Ablation of cardiac tissue using focused radiotherapy to control ventricular tachycardia (VT) is a novel therapeutic consideration in the management of ventricular arrhythmias associated with structural heart disease. Segments of ventricular myocardium that act as substrates for ventricular tachycardia can be identified by the use of invasive mapping techniques or non-invasive ECG incorporating multi-electrode body surface recordings and cardiac imaging. Early case series have demonstrated a consistent decrease in VT burden and sufficient acute safety to expand to more detailed multicenter studies. As VT substrates can be closely related to critical structures such as the epicardial coronary vessels and the conduction system, the late effects of radiation to these structures is of concern. Modeling radiation dose to these structures has a potentially important role in application of this new technology. This review details the current technique of stereotactic body radiotherapy for control of VT and provides approximated dose calculations to collateral structures when therapy is targeted at the base of the heart.


Subject(s)
Body Surface Potential Mapping , Heart Conduction System/diagnostic imaging , Heart Ventricles/diagnostic imaging , Tachycardia, Ventricular/diagnostic imaging , Tachycardia, Ventricular/radiotherapy , Coronary Vessels/diagnostic imaging , Coronary Vessels/physiopathology , Electrocardiography , Heart Conduction System/physiopathology , Heart Diseases/physiopathology , Heart Ventricles/physiopathology , Humans , Image Processing, Computer-Assisted , Models, Theoretical , Myocardium/pathology , Radiosurgery , Risk , Signal Processing, Computer-Assisted
9.
Pediatr Blood Cancer ; 65(2)2018 Feb.
Article in English | MEDLINE | ID: mdl-28905489

ABSTRACT

Optimal treatment of rhabdomyosarcoma (RMS) requires multidisciplinary approach, incorporating chemotherapy with local control. Although current therapies are built on cooperative group trials, a comprehensive standard of care to guide clinical decision making has been lacking, especially for relapsed patients. Therefore, we assembled a panel of pediatric and adolescent and young adult sarcoma experts to develop treatment guidelines for managing RMS and to identify areas in which further research is needed. We created algorithms incorporating evidence-based care for patients with RMS, emphasizing the importance of clinical trials and close integration of all specialties involved in the care of these patients.


Subject(s)
Algorithms , Evidence-Based Medicine/methods , Rhabdomyosarcoma/therapy , Clinical Trials as Topic , Humans , Practice Guidelines as Topic
10.
Am J Clin Oncol ; 41(5): 471-475, 2018 05.
Article in English | MEDLINE | ID: mdl-27841802

ABSTRACT

OBJECTIVE: Cancer mortality is a leading cause of disease-related death in the adolescent and young adult (AYA) population. Compared with older and younger patients, AYA patients often experience worse cancer-specific outcomes. Here, we compare AYA and pediatric overall survival (OS) in the most common pediatric extracranial solid tumors. MATERIALS AND METHODS: Using the US Surveillance, Epidemiology, and End Results database, we studied patients (age, 0 to 39 y) diagnosed with Ewing sarcoma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and Wilms tumor. RESULTS: A total of 12,375 patients (age, 0 to 39 y) were diagnosed between 1973 and 2010 (8247 pediatric and 4128 AYA patients). AYA patients with rhabdomyosarcoma and Ewing sarcoma were more likely to present with metastatic disease. OS was significantly worse in the AYA cohort for all tumor types (P<0.001) with the exception of osteosarcoma (P=0.29). Across 2 treatment time periods (1973 to 1989 and 1990 to 2010), there was significant improvement in 5-year OS in all tumor types with the exception of rhabdomyosarcoma; however, AYA patients continued to experience worse OS in the modern treatment cohort with the exception of osteosarcoma patients. There was no improvement in OS among AYA patients with Ewing sarcoma, neuroblastoma, rhabdomyosarcoma, or Wilms tumor over the 2 treatment eras. CONCLUSIONS: For the most common pediatric extracranial solid tumors, AYA patients experience significantly worse OS compared with pediatric patients. Although improvements in therapy have led to gain in survival for pediatric patients, with the exception of osteosarcoma, AYA experienced no increase in survival over the study period. This investigation demonstrates the importance for further research in the AYA population.


Subject(s)
Healthcare Disparities/statistics & numerical data , Neoplasms/mortality , SEER Program/statistics & numerical data , Adolescent , Adult , Age Factors , Bone Neoplasms/diagnosis , Bone Neoplasms/mortality , Bone Neoplasms/therapy , Child , Child, Preschool , Cohort Studies , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Infant , Infant, Newborn , Kidney Neoplasms/diagnosis , Kidney Neoplasms/mortality , Kidney Neoplasms/therapy , Male , Neoplasms/diagnosis , Neoplasms/therapy , Neuroblastoma/diagnosis , Neuroblastoma/mortality , Neuroblastoma/therapy , Osteosarcoma/diagnosis , Osteosarcoma/mortality , Osteosarcoma/therapy , Prognosis , Rhabdomyosarcoma/diagnosis , Rhabdomyosarcoma/mortality , Rhabdomyosarcoma/therapy , Sarcoma, Ewing/diagnosis , Sarcoma, Ewing/mortality , Sarcoma, Ewing/therapy , Survival Rate , Time Factors , Wilms Tumor/diagnosis , Wilms Tumor/mortality , Wilms Tumor/therapy , Young Adult
11.
J Neurooncol ; 136(2): 385-394, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29209874

ABSTRACT

To assess the utilization and outcomes of adjuvant monotherapy with hypofractionated radiation (RT) among elderly patients not receiving traditional adjuvant chemoradiotherapy (cRT) for glioblastoma multiforme (GBM). A retrospective analysis using the National Cancer Data Base with GBM patients aged 65 years or older treated between 2005 and 2012 was conducted. Patients who underwent hypofractionated RT (40 Gy), conventional RT (60 Gy), chemotherapy, or best supportive care alone were included. Statistical methods included logistic regression for utilization and Cox regression for survival analysis. A total of 9556 patients were analyzed. On multivariate analysis (compared to those receiving conventional RT), patients more likely to be treated with hypofractionated RT were older (75-84 years old OR 2.05; p < 0.01 and ≥ 85 years old OR 3.32; p < 0.01), with a Charlson/Deyo score of 2 or higher (OR 1.80; p = 0.05), from communities > 50 miles from their treatment facility (50-100 miles OR 8.03; p < 0.01 and > 100 miles OR 7.16; p < 0.01), treated at an Academic/Research facility (OR 2.85; p = 0.04), and diagnosed between 2011 and 2012 (OR 4.15; p < 0.01). On Cox regression, hypofractionated RT (HR 0.65; p < 0.01), conventional RT (HR 0.60; p < 0.01), and chemotherapy alone (HR 0.69; p < 0.01) were all associated with decreased risk of death compared to no adjuvant therapy. Among patients receiving adjuvant treatment, utilization of hypofractionated RT increased from 7 to 19% during the study period. Among elderly patients with GBM not receiving cRT, the utilization of adjuvant monotherapy with hypofractionated RT has increased over time. Retrospective evidence suggests it may be better than best supportive care alone and as good as conventionally fractionated RT alone.


Subject(s)
Brain Neoplasms/radiotherapy , Glioblastoma/radiotherapy , Radiation Dose Hypofractionation , Aged , Aged, 80 and over , Databases, Factual , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Radiotherapy, Adjuvant/statistics & numerical data , Retrospective Studies , Treatment Outcome
12.
J Pediatr Hematol Oncol ; 39(5): 382-387, 2017 07.
Article in English | MEDLINE | ID: mdl-28538508

ABSTRACT

To investigate the determinants of radiation therapy refusal in pediatric cancer, we used the Surveillance, Epidemiology, and End Results registry to identify 24,421 patients who met the eligibility criteria, diagnosed between 1974 and 2012. Patients had any stage of cancer, were aged 0 to 19, and received radiation therapy or refused radiation therapy when it was recommended. One hundred twenty-eight patients (0.52%) refused radiation therapy when it was recommended. Thirty-two percent of patients who refused radiation therapy ultimately died from their cancer, at a median of 7 months after diagnosis (95% confidence interval, 3-11 mo), as compared with 29.0% of patients who did not refuse radiation therapy died from their cancer, at a median of 17 months after diagnosis (95% confidence interval, 17-18 mo). On multivariable analysis, central nervous system (CNS) site, education, and race were associated with radiation refusal. The odds ratio for radiation refusal for patients with CNS disease was 1.62 (P=0.009) as compared with patients without CNS disease. For patients living in a county with ≥10% residents having less than ninth grade education, the odds ratio for radiation refusal was 1.71 (P=0.008) as compared with patients living in a county with <10% residents having less than ninth grade education. Asian, Pacific Islander, Alaska Native, and American Indian races had an odds ratio of 2.12 (P=0.002) for radiation refusal as compared with black or white race. Although the radiation refusal rate in the pediatric cancer population is low, we show that CNS site, education level, and race are associated with a significant difference in radiation refusal.


Subject(s)
Central Nervous System Diseases , Education , Neoplasms/radiotherapy , Racial Groups , Treatment Refusal , Adolescent , Child , Humans , Infant , Neoplasms/mortality , Radiotherapy , Treatment Refusal/ethnology , Treatment Refusal/psychology , Young Adult
13.
Cancer ; 123(12): 2206-2218, 2017 Jun 15.
Article in English | MEDLINE | ID: mdl-28323337

ABSTRACT

When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are complex and require a multidisciplinary approach. This review presents scenarios commonly encountered in the therapy of bone sarcomas with the goal of objectively presenting a consensus, multidisciplinary management approach. Little variation was found in the authors' group with respect to local control or systemic therapy. Clinical trials were universally prioritized in all settings. Decisions regarding relapse therapies in the absence of a clinical trial had very minor variations initially, but a consensus was reached after a literature review and discussion. This review presents a concise document and figures as a starting point for evidence-based care for patients with these rare diseases. This framework allows prospective decision making and prioritization of clinical trials. It is hoped that this framework will inspire and focus future clinical research and thus lead to new trials to improve efficacy and reduce toxicity. Cancer 2017;123:2206-2218. © 2017 American Cancer Society.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/therapy , Clinical Decision-Making , Neoplasm Recurrence, Local/therapy , Orthopedic Procedures , Osteosarcoma/therapy , Radiotherapy , Sarcoma, Ewing/therapy , Adolescent , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/pathology , Child , Clinical Trials as Topic , Combined Modality Therapy , Humans , Osteosarcoma/diagnostic imaging , Osteosarcoma/pathology , Patient Care Team , Sarcoma/diagnostic imaging , Sarcoma/pathology , Sarcoma/therapy , Sarcoma, Ewing/diagnostic imaging , Sarcoma, Ewing/pathology , Young Adult
14.
Cancer ; 123(4): 682-687, 2017 02 15.
Article in English | MEDLINE | ID: mdl-27861763

ABSTRACT

BACKGROUND: Atypical teratoid rhabdoid tumors (ATRTs) are rare brain tumors that occur primarily in children under the age of 3 years. This report evaluates the treatment approach and survival outcomes in a large cohort of patients treated in the United States. METHODS: Using the National Cancer Database, the analysis included all ATRT patients aged 0 to 18 years who were diagnosed between 2004 and 2012 and had complete treatment data. RESULTS: Three hundred sixty-one ATRT patients were evaluated. The 5-year overall survival (OS) rate was 29.9%, and it was significantly lower for children who were less than 3 years old (5-year OS, 27.7%) versus those who were 3 years old or older (5-year OS, 37.5%; P < .001). The best outcome was seen for patients with localized disease who received trimodality therapy (surgery, chemotherapy, and radiation therapy [RT]) with a 5-year OS rate of 46.8%. The utilization of trimodality therapy significantly increased during the study period (27.7% in 2004-2008 vs 45.1% in 2009-2012; P < .01), largely because of the increased use of RT. In a multivariate analysis, treatment that did not utilize trimodality therapy was associated with significantly worse OS (hazard ratio, 2.52; 95% confidence interval (1.82-3.51). Children aged 0 to 2 years were significantly less likely to receive trimodality therapy because of decreased utilization of RT in this age group. CONCLUSIONS: The use of trimodality therapy significantly increased during the study period and was associated with improved outcomes. For patients with localized disease who received trimodality therapy, the OS rate at 5 years approached 50%. However, further research into the optimal management of children less than 3 years old is needed because of their significantly worse OS in comparison with older children. Cancer 2017;123:682-687. © 2016 American Cancer Society.


Subject(s)
Central Nervous System Neoplasms/epidemiology , Rhabdoid Tumor/epidemiology , Teratoma/epidemiology , Adolescent , Central Nervous System Neoplasms/drug therapy , Central Nervous System Neoplasms/radiotherapy , Central Nervous System Neoplasms/surgery , Child , Child, Preschool , Combined Modality Therapy , Databases, Factual , Female , Humans , Infant , Infant, Newborn , Male , Proportional Hazards Models , Rhabdoid Tumor/drug therapy , Rhabdoid Tumor/radiotherapy , Rhabdoid Tumor/surgery , Survival Analysis , Teratoma/drug therapy , Teratoma/radiotherapy , Teratoma/surgery , Treatment Outcome
15.
J Pediatr Hematol Oncol ; 38(5): 350-4, 2016 07.
Article in English | MEDLINE | ID: mdl-27177145

ABSTRACT

With modern therapy, overall survival (OS) for children with acute lymphoblastic leukemia approaches 90%. However, inferior outcomes for minority children have been reported. Data on the effects of ethnicity/race as it relates to socioeconomic status are limited. Using state cancer registry data from Texas and Florida, we evaluated the impact of neighborhood-level poverty rate and race/ethnicity on OS for 4719 children with acute lymphoblastic leukemia. On multivariable analysis, patients residing in neighborhoods with the highest poverty rate had a 1.8-fold increase in mortality compared with patients residing in neighborhoods with the lowest poverty rate (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.41-2.30). Hispanic and non-Hispanic black patients also had increased risk of mortality compared with non-Hispanic white patients (Hispanic: HR, 1.18; 95% CI, 1.01-1.39; non-Hispanic black: HR, 1.31; 95% CI, 1.03-1.66). On subgroup analysis, there was a 21.7% difference in 5-year OS when comparing non-Hispanic white children living in the lowest poverty neighborhoods (5-year OS, 91.2%; 95% CI, 88.6-93.2) to non-Hispanic black children living in the highest poverty neighborhoods (5-year OS, 69.5%; 95% CI, 61.5-76.1). To address such disparities in survival, further work is needed to identify barriers to cancer care in this pediatric population.


Subject(s)
Ethnicity , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Racial Groups , Social Class , Adolescent , Child , Child, Preschool , Female , Florida , Humans , Infant , Male , Minority Groups , Poverty , Precursor Cell Lymphoblastic Leukemia-Lymphoma/economics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/ethnology , Registries , Survival Rate , Texas , Treatment Outcome
16.
Int J Radiat Oncol Biol Phys ; 94(4): 691-9, 2016 Mar 15.
Article in English | MEDLINE | ID: mdl-26972641

ABSTRACT

PURPOSE: Breast-conserving therapy (BCT) is a recommended alternative to mastectomy (MT) for early-stage breast cancer. Limited access to radiation therapy (RT) may result in higher rates of MT. We assessed the association between distance to the nearest RT facility and the use of MT, in a modern cohort of women. METHODS AND MATERIALS: Women with stage 0-II breast cancer eligible for BCT diagnosed from 2004 to 2010 were identified from the Florida Cancer Data System (FCDS). Distances from patient census tracts to the nearest RT facility census tract were calculated. Multivariate logistic regression was used to identify explanatory variables that influenced MT use. RESULTS: Of the 27,489 eligible women, 32.1% (n=8841) underwent MT, and 67.8% (n=18,648) underwent BCS. Thirty-two percent of patients lived in a census tract that was >5 miles from an RT facility. MT use increased with increasing distance to RT facility (31.1% at ≤5 miles, 33.8% at >5 to <15 miles, 34.9% at 15 to <40 miles, and 51% at ≥40 miles, P<.001). The likelihood was that MT was independently associated with increasing distance to RT facility on multivariate analysis (P<.001). Compared to patients living <5 miles away from an RT facility, patients living 15 to <40 miles away were 1.2 times more likely to be treated with MT (odds ratio [OR]: 1.19, 95% confidence interval [CI]: 1.05-1.35, P<.01), and those living ≥40 miles away were more than twice as likely to be treated with MT (OR: 2.17, 95% CI: 1.48-3.17, P<.001). However, in patients younger than 50 years (n=5179), MT use was not associated with distance to RT facility (P=.235). CONCLUSIONS: MT use in a modern cohort of women is independently associated with distance to RT facility. However, for young patients, distance to RT is not a significant explanatory variable for MT use.


Subject(s)
Breast Neoplasms/surgery , Cancer Care Facilities/statistics & numerical data , Health Services Accessibility/statistics & numerical data , Mastectomy/statistics & numerical data , Adult , Age Factors , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Censuses , Female , Humans , Mastectomy, Segmental/statistics & numerical data , Middle Aged , Odds Ratio , Regression Analysis , Socioeconomic Factors , Young Adult
17.
J Med Imaging Radiat Oncol ; 60(1): 119-28, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26439449

ABSTRACT

INTRODUCTION: Local control, either with surgery, radiation (RT) or both, is essential in the management of localised Ewing sarcoma; however, the relative role of RT remains controversial. METHODS: Using the Surveillance, Epidemiology, and End Results database, 612 patients treated for non-metastatic skeletal Ewing sarcoma between the years 1988 and 2010 were identified. RESULTS: Median age and follow-up were 13 years (range: 0-21) and 56 months (range: 0-287), respectively. Five-year overall survival (OS) for the cohort was 74.4 ± 2.0%. Patients received surgery alone (51.3%), RT alone (21.6%) or both (27.1%). Patients with skeletal Ewing sarcoma had improved OS with surgery alone compared with other treatments. However, in subset analyses, RT was not inferior to surgery alone for appendicular (5-year OS: 80.0% vs. 79.3%), non-pelvic (84.3% vs. 79.9%) or localised disease (confined to cortex or periosteum; 79.7% vs. 80.6%). After controlling for stage and site, no increase in mortality was observed with RT versus surgery alone (hazard ratio = 0.77 (95% confidence interval: 0.49-1.19)). CONCLUSIONS: In regard to survival, RT did not appear to be inferior to surgery alone for most patients, particularly those with disease at favourable sites (localised, appendicular, non-pelvic). In select patients with Ewing sarcoma, RT may be an appropriate strategy for local control that does not necessarily compromise survival outcomes.


Subject(s)
Bone Neoplasms/mortality , Bone Neoplasms/radiotherapy , Radiotherapy, Conformal/mortality , Radiotherapy, Conformal/statistics & numerical data , Sarcoma, Ewing/mortality , Sarcoma, Ewing/radiotherapy , Adolescent , Bone Neoplasms/secondary , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Longitudinal Studies , Male , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/prevention & control , Prevalence , Sarcoma, Ewing/secondary , Survival Rate , Tennessee/epidemiology , Treatment Outcome , Young Adult
18.
J Neurooncol ; 122(2): 321-7, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25557108

ABSTRACT

The diagnosis of pediatric medulloblastoma now carries a much improved overall survival; however as outcomes advance, late mortality, from causes such as disease recurrence and subsequent malignancies, are of increasing concern for these patients. Using the Surveillance, Epidemiology, and End Results database, the causes of late mortality in long term survivors of medulloblastoma were evaluated. Patients diagnosed with a medulloblastoma between the ages of 0-19 years who survived at least 5 years after diagnosis were included. Using U.S. population data, standardized mortality ratios (SMRs) were calculated. Cumulative incidence estimates and standardized incidence ratios (SIRs) of subsequent malignancies were calculated. A total of 455 patients were included in the analysis. All patients received radiation as part of therapy. Median age at diagnosis was 7 years, and mean follow-up was 16 years. By the time of last follow-up, 20.4 % of patients had died, representing an SMR of 24.0 (95 % CI 19.3-29.4). Overall survival at 30 years was 65.5 %. Primary recurrence accounted for 59 % of late deaths, while subsequent malignancy accounted for 11.8 %. SIR for subsequent malignancy in these patients was 10.4 (95 % CI 6.9-15.1). The most common secondary tumor was another brain tumor (32 %), followed by thyroid cancer (21 %). These data demonstrate that late mortality remains a significant problem in these patients. The causes of death are largely attributable to disease recurrence and secondary malignancies. Efforts to improve risk stratification and tailor therapy will help in reducing late mortality in this population.


Subject(s)
Medulloblastoma/mortality , Survivors , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Incidence , Infant , Infant, Newborn , Kaplan-Meier Estimate , Male , Medulloblastoma/physiopathology , Medulloblastoma/therapy , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/physiopathology , Neoplasms, Second Primary/mortality , Neoplasms, Second Primary/physiopathology , Young Adult
19.
J Pain Symptom Manage ; 49(6): 1081-1087.e4, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25596010

ABSTRACT

CONTEXT: Patients with metastatic non-small cell lung cancer (NSCLC) have limited survival. Population studies have evaluated the impact of radiation refusal in the curative setting; however, no data exist concerning the prognostic impact of radiation refusal in the palliative care setting. OBJECTIVES: To investigate the patterns of radiation refusal in newly diagnosed patients with metastatic NSCLC. METHODS: Patients with Stage IV NSCLC diagnosed between 1988 and 2010 were identified in the Surveillance, Epidemiology, and End Results database. Univariate and multivariate analyses were used to identify predictors for refusal of radiation and the impact of radiation and refusal on survival in the palliative setting. RESULTS: A total of 285,641 patients were initially included in the analysis. Palliative radiation was recommended in 42% and refused by 3.1% of patients. Refusal rates remained consistent across included years of study. On multivariate analysis, older, nonblack/nonwhite, unmarried females were more likely to refuse radiation (P < 0.001 in all cases). Median survival for patients refusing radiation was three months vs. five months for those receiving radiation and two months for those whom radiation was not recommended. CONCLUSION: Patients with metastatic NSCLC who refuse recommended palliative radiation have a poor survival. Radiation refusal or the recommendation against treatment can serve as a trigger for integrating palliative care services sooner and contributes greatly to prognostic awareness. Further investigation into this survival difference and the factors behind refusal are warranted.


Subject(s)
Carcinoma, Non-Small-Cell Lung/epidemiology , Carcinoma, Non-Small-Cell Lung/radiotherapy , Palliative Care/methods , Treatment Refusal/statistics & numerical data , Age Factors , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Kaplan-Meier Estimate , Male , Marital Status , Middle Aged , Multivariate Analysis , Neoplasm Staging , Prognosis , Sex Factors
20.
Neuro Oncol ; 17(5): 741-6, 2015 May.
Article in English | MEDLINE | ID: mdl-25422317

ABSTRACT

BACKGROUND: Pediatric and young adult central nervous system (CNS) germinomas have favorable cure rates. However, long-term follow-up data are limited because of the rarity of this tumor. We report the long-term overall survival (OS) and causes of late mortality for these patients. METHODS: Data between 1973 and 2005 from the Surveillance, Epidemiology, and End Results (SEER) database were analyzed. Kaplan Meier survival analysis was performed on 5-year survivors of childhood CNS germinomatous germ cell tumors (GGCTs) and nongerminomatous germ cell tumors (NGGCTs). Standardized mortality ratios (SMRs) were calculated using US population data to compare observed versus expected all-cause death and death from stroke. Cumulative incidence was calculated using a competing risk model. RESULTS: Four hundred five GGCTs and 94 NGGCTs cases were eligible. OS at 20 and 30 years for GGCTs was 84.1% and 61.9%, respectively, and was 86.7% for NGGCTs at both time points. Five-year survivors of GGCTs and NGGCTs experienced a 10-fold increase in mortality risk compared with their peers (SMR, 10.41; 95% confidence interval [CI], 7.71-13.76 vs SMR, 10.39;95% CI, 4.83-19.73, respectively). Five-year survivors GGCTs also experienced a nearly 59-fold increase in risk of death from stroke (SMR, 58.93; 95% CI, 18.72-142.10). At 25 years, the cumulative incidence of death due to cancer and subsequent malignancy was 16% and 6.0%, respectively. CONCLUSION: Although CNS germinomas have favorable cure rates, late recurrences, subsequent malignancies, and stroke significantly affect long-term survival. Close attention to long-term follow-up with assessment of stroke risk factors is recommended.


Subject(s)
Brain Neoplasms/mortality , Germinoma/mortality , Adolescent , Brain Neoplasms/epidemiology , Cause of Death , Child , Female , Germinoma/epidemiology , Humans , Incidence , Kaplan-Meier Estimate , Male , Registries , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...